280 related articles for article (PubMed ID: 19017562)
1. Discovery and development of heat shock protein 90 inhibitors.
Taldone T; Sun W; Chiosis G
Bioorg Med Chem; 2009 Mar; 17(6):2225-35. PubMed ID: 19017562
[TBL] [Abstract][Full Text] [Related]
2. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
Hadden MK; Lubbers DJ; Blagg BS
Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
[TBL] [Abstract][Full Text] [Related]
3. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
4. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
[TBL] [Abstract][Full Text] [Related]
5. Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitors.
Austin C; Pettit SN; Magnolo SK; Sanvoisin J; Chen W; Wood SP; Freeman LD; Pengelly RJ; Hughes DE
J Biomol Screen; 2012 Aug; 17(7):868-76. PubMed ID: 22573733
[TBL] [Abstract][Full Text] [Related]
6. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
Khandelwal A; Crowley VM; Blagg BSJ
Med Res Rev; 2016 Jan; 36(1):92-118. PubMed ID: 26010985
[TBL] [Abstract][Full Text] [Related]
7. Emerging Hsp90 inhibitors: from discovery to clinic.
Chiosis G; Rodina A; Moulick K
Anticancer Agents Med Chem; 2006 Jan; 6(1):1-8. PubMed ID: 16475922
[TBL] [Abstract][Full Text] [Related]
8. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
Sharp SY; Boxall K; Rowlands M; Prodromou C; Roe SM; Maloney A; Powers M; Clarke PA; Box G; Sanderson S; Patterson L; Matthews TP; Cheung KM; Ball K; Hayes A; Raynaud F; Marais R; Pearl L; Eccles S; Aherne W; McDonald E; Workman P
Cancer Res; 2007 Mar; 67(5):2206-16. PubMed ID: 17332351
[TBL] [Abstract][Full Text] [Related]
9. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.
Marcu MG; Chadli A; Bouhouche I; Catelli M; Neckers LM
J Biol Chem; 2000 Nov; 275(47):37181-6. PubMed ID: 10945979
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibition with resorcyclic acid lactones (RALs).
Winssinger N; Fontaine JG; Barluenga S
Curr Top Med Chem; 2009; 9(15):1419-35. PubMed ID: 19860733
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
12. Development of purine-scaffold small molecule inhibitors of Hsp90.
Chiosis G; Lucas B; Huezo H; Solit D; Basso A; Rosen N
Curr Cancer Drug Targets; 2003 Oct; 3(5):371-6. PubMed ID: 14529388
[TBL] [Abstract][Full Text] [Related]
13. Purine-scaffold Hsp90 inhibitors.
Taldone T; Chiosis G
Curr Top Med Chem; 2009; 9(15):1436-46. PubMed ID: 19860732
[TBL] [Abstract][Full Text] [Related]
14. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
15. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.
Marcu MG; Schulte TW; Neckers L
J Natl Cancer Inst; 2000 Feb; 92(3):242-8. PubMed ID: 10655441
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel Hsp90 C-terminal domain inhibitors that disrupt co-chaperone binding.
Mak OW; Sharma N; Reynisson J; Leung IKH
Bioorg Med Chem Lett; 2021 Apr; 38():127857. PubMed ID: 33609661
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-pyridoyl-Δ
Kadasi S; Yerroju R; Gaddam S; Pullanagiri N; Chary M; Pingili D; Raj S; Raghavendra NM
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900192. PubMed ID: 31808979
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Soga S; Akinaga S; Shiotsu Y
Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
[TBL] [Abstract][Full Text] [Related]
19. Evidence that the novobiocin-sensitive ATP-binding site of the heat shock protein 90 (hsp90) is necessary for its autophosphorylation.
Langer T; Schlatter H; Fasold H
Cell Biol Int; 2002; 26(7):653-7. PubMed ID: 12127946
[TBL] [Abstract][Full Text] [Related]
20. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
